Web1 day ago · Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has … WebWhat this study adds: This study fills gaps regarding the efficacy of immunotherapy combined with chemotherapy as first-line treatment for ES-SCLC, and provides better …

Program Guide – ASCO Meeting Program Guide

Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic nonsmall-cell lung cancer (NSCLC) lacking sensitizing EGFR or ALK mutations. Pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, Bristol-Myers Squibb), and atezolizumab (Tecentriq, Genentech) are approved as … See more Patients who were at least 18 years of age were eligible for enrollment if they had pathologically confirmed metastatic nonsquamous … See more The trial was designed by a panel of academic advisors and employees of Merck (in Kenilworth, New Jersey), the trial sponsor. An external monitoring committee oversaw … See more In this double-blind trial, patients were randomly assigned, in a 2:1 ratio, to receive either 200 mg of pembrolizumab or saline placebo, both administered intravenously every 3 weeks for up to 35 cycles. … See more Efficacy was assessed in the intention-to-treat population, which included all the patients who had undergone randomization. Safety was assessed in the as-treated population, which included all patients who had … See more WebPD-L1 score was defined as the proportion of tumor cells stained by the assay and analysis was conducted for patients with tumor PD-L1 score ≥50%. OS, PFS, and ORR were compared between chemo-IO and IO alone via a pooled analysis. Median survival times were estimated using Kaplan-Meier methods. phisher setup

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 …

WebJul 3, 2024 · who showed the efficacy of adding pembrolizumab to standard chemotherapy in patients with PD-L1-positive metastatic triple-negative breast cancer. One feature of this study is the inclusion of patients with early recurrences (between 6 months and 12 months following completion of perioperative chemotherapy), which are common in triple … WebChemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC J Thorac Oncol. 2024 Apr;17(4):503-509. doi: … WebNov 13, 2024 · Randomization was stratified by chemotherapy treatment (pac or nab-paclitaxel vs. gem and carbo), tumor PD-L1 expression (CPS ≥1 vs. CPS <1) according to the PD-L1 IHC 22C3 pharmDx kit and prior treatment with the same class of chemotherapy in the neoadjuvant setting (yes vs. no). phisherprice